Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
WYND Wyndham Destinations Inc
GRWWF Great Wall Pan Asia Holdings Ltd
BAC Bank of America Corp
FULC Fulcrum Therapeutics Inc
T AT&T Inc
F Ford Motor Co
JNJ Johnson & Johnson
HHER Her Imports
WSBF Waterstone Financial Inc
Go

Health Care : Biotechnology | Small Cap Value
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited is a clinical-stage oncology and immunology focused biopharmaceutical company. The Company’s portfolio is comprised of one monoclonal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology. The Company’s products include ASLAN004, ASLAN003 and Varlitinib. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN003 is an inhibitor of human dihydroorotate dehydrogenase (DHODH), in acute myeloid leukemia (AML) and are exploring development in other solid tumors. Varlitinib is an oral, reversible small-molecule pan-HER inhibitor.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$1.64
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
84,477
0

Facebook stock jumps 9% to record high after profit tops $5 billion

9:55 am ET July 31, 2020 (MarketWatch)
Print

Facebook Inc. (FB) shares rocketed more than 7% to new highs Friday morning following an earnings report that showed the social-media company collected more than $5 billion in profit (http://www.marketwatch.com/story/facebook-shares-rally-as-quarterly-result-easily-top-street-view-2020-07-30) despite a worldwide pandemic and targeted ad boycott. Facebook stock opened at $255.82, 9.1% higher than Thursday's closing price, giving it a market capitalization of roughly $730 billion. Major advertisers have committed to boycotting Facebook in July (http://www.marketwatch.com/story/the-facebook-ad-boycott-could-pay-off-for-companies-more-than-advertising-on-facebook-2020-07-01) to protest its inability to prevent hateful posts, violence and misinformation on its platform, but the company said Thursday afternoon that it doesn't expect much to change financially as a result. "We expect our full-quarter Q3 year-over-year ad revenue growth rate to be roughly similar to this" quarter that was reported Thursday, Chief Financial Officer David Wehner said in a conference call. Facebook shares have gained more than 23% this year, as the S&P 500 index has added 0.5%.

-Jeremy C. Owens; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 31, 2020 09:55 ET (13:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.